Basic Information
LncRNA/CircRNA Name | ENSG00000240990 |
Synonyms | HOXA11-AS, HOXA-AS5, HOXA11-AS1, HOXA11AS, HOXA11S, NCRNA00076 |
Region | GRCh38_7:27184518-27189293 |
Ensemble | ENSG00000240990 |
Refseq | NR_002795 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | Enoxacin and Etoposide, CDF (analogues of curcumin) | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | lung adenocarcinoma |
ICD-0-3 | C34 |
Methods | DNA methylation etc. |
Sample | cell lines |
Expression Pattern | differential expression |
Function Description | competing endogenous RNA network analysis inferred that lncRNA ENSG00000240990 competed with HOXA10 to absorb hsa-let-7a/b/f/g-5p and affected patient prognosis in LUAD. Last but not least, by integrating target information of miRNA we also provided a new perspective for the discovery of potential small molecule drugs. Some small molecule drugs, such as Enoxacin and Etoposide, regulated the competitive relations of lncRNA-PCG pairs by influencing the expression of hsa-let-7a/b/f/g-5p, which provided novel clues for LUAD treatment. Therefore, we combined the information that was provided by SM2miR [67] with the module to infer potential small molecule drugs for LUAD treatment. In the ceRNA module, some potential drugs could up-regulate the hsa-let-7a/b/f/g-5p expression and further down-regulate the expression of related lncRNAs/PCGs and contribute to the treatment of LUAD ((Figure10)). |
Pubmed ID | 29069717 |
Year | 2017 |
Title | Integrated analysis of dosage effect lncRNAs in lung adenocarcinoma based on comprehensive network. |
External Links
Links for ENSG00000240990 | GenBank HGNC NONCODE |
Links for lung adenocarcinoma | OMIM COSMIC |